1
* Not all systems shown available worldwide.
2
Budi Gunadi Sadikin
Minister of Health
Republic of Indonesia
3
La storia del programma
2006
Cepheid investe nello sviluppo dei sistemi GeneXpert®
2006
L’OMS lancia la strategia Stop TB durante la giornata mondiale della TB
2006
Cepheid, FIND, University of Medicine and Dentistry of New Jersey (Rutgers University), and NIAID collaborate to develop Xpert® MTB/RIF* for TB with a grant from the Bill & Melinda Gates Foundation
2009–2010
Lancio del test Xpert MTB/RIF* che ottiene l’approvazione dell’OMS
Accesso globale
2011
Cepheid stabilisce ufficialmente il Global Access Program
2006
In risposta agli alti tassi di coinfezione TB-HIV nei Paesi rientranti nel Global Access Program, Cepheid e FIND collaborano allo sviluppo del test per la determinazione della carica virale* (Viral Load, VL) di HIV-1 Xpert.
2014
Xpert® HPV* and Xpert HIV-1 VL* tests launch
2015
Cepheid develops and launches Xpert® Ebola test to respond to West African outbreak with funding support from the Paul G. Allen and Bill & Melinda Gates Foundations
2016
WHO prequalifies Xpert HIV-1 Qual*
2017
WHO prequalifies Xpert HCV VL*, Xpert HIV-1 VL*, and Xpert HPV*; Xpert® MTB/RIF Ultra* launches and gets WHO endorsement
2020
Xpert® MTB/XDR* launches to detect multidrug-resistant TB with new 10-color multiplexing technology
2020
Xpert® Xpress SARS-CoV-2" launches
Programma di accesso globale oggi
GeneXpert systems available in multiple modular configuration options 15 tests available under Global Access Program, 7 of which are endorsed or pre-qualified by WHO
* CE-IVD. Dispositivo medico diagnostico in vitro. Potrebbe non essere disponibile in alcuni Paesi. Non disponibile negli Stati Uniti.
IVD. Dispositivo medico diagnostico in vitro. Potrebbe non essere disponibile in alcuni Paesi.
^ Da utilizzare nell’ambito dell’autorizzazione all’uso in emergenza negli Stati Uniti d’America.
Dr. Tereza Kasaeva, Director, Global Tuberculosis Programme, WHO World TB Day 2023, Interview with Dr. Tereza Kasaeva
https://www.youtube.com/watch?v=AL_t8LZkD8Y
2. Journal of Benefit-Cost Analysis (2023) https://www.cambridge.org/core/journals/journal-of-benefit-cost-analysis/article/one-million-lives-saved-per-year-a-costbenefit-analysis-of-the-global-plan-to-end-tuberculosis-20232030-and-beyond/A74F0D10F1017092A250EB604ED39B1B
3. Message from the Executive Director: Global Fund Investments in Health and Laboratory-related Equipment; 21 gennaio 2024
https://www.theglobalfund.org/en/oig/updates/2024-01-26-message-executive-director-global-fund-investments-health-laboratory-related-equipment/
4. Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria.
From the TB Innovation Summit https://www.stoptb.org/news/global-health-and-business-leaders-pledge-major-commitments-to-end-tuberculosis